In instances where hypokalemia occurred after CII was started, the serum potassium level at the start of treatment was significantly lower (p=0.003), and the insulin flow rate per body weight was significantly higher (p=0.013; Figure 3A). The gene discussed is INS; the disease is Hypokalemia.